HR 6102

VALID Act of 2020

Congress: 116 (2019–2021, Ended)
Chamber: House
Policy Area: Health
Introduced: Mar 5, 2020
Current Status: Referred to the House Committee on Energy and Commerce.
Latest Action: Referred to the House Committee on Energy and Commerce. (Mar 5, 2020)
Official Text: https://www.congress.gov/bill/116th-congress/house-bill/6102

Sponsor

Name: Rep. DeGette, Diana [D-CO-1]
Party: Democratic • **State:** CO • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bucshon, Larry [R-IN-8]	R · IN		Mar 5, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Mar 5, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 3404	Identical bill	**Mar 5, 2020:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Mar 5, 2020)

Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020

This bill requires the Food and Drug Administration to regulate in vitro clinical tests (i.e., tests intended for the collection, preparation, analysis, or in vitro clinical examination of specimens from the human body in order to provide information about a disease, condition, or treatment for a disease or condition).

Actions Timeline

- **Mar 5, 2020:** Introduced in House
- **Mar 5, 2020:** Referred to the House Committee on Energy and Commerce.